Related Experiment Video
Updated: Aug 8, 2026

Use of the Operant Orofacial Pain Assessment Device (OPAD) to Measure Changes in Nociceptive Behavior
Published on: June 10, 2013
Evidence that cholecystokinin-enhanced retention is mediated by changes in opioid activity in the amygdala
J F Flood1, J S Garland, J E Morley
1VA Medical Center, Geriatric Research Educational and Clinical Center, St. Louis, MO 63106.
Abstract:
Mice, partially trained to avoid footshock in a T-maze, showed enhanced retention relative to vehicle-injected mice when treated peripherally with arecoline, D-amphetamine, cholecystokinin octapeptide (CCK-8), epinephrine or naloxone. Both intra-amygdaloid and intraventricular injections of beta-endorphin resulted in amnesia. D-amphetamine and arecoline blocked the amnestic effect of beta-endorphin administered into the amygdala but it required higher doses for CCK-8, epinephrine and naloxone to block the amnestic effect of beta-endorphin. The effects of CCK-8, epinephrine and naloxone showed a differential ability to block amnesia induced by beta-endorphin intraventricularly with epinephrine and naloxone preventing amnesia but CCK-8 not improving retention. This data suggests that the memory enhancement produced by peripherally administered CCK-8 involves the amygdala and that both CCK-8 and epinephrine interact with opioid amnestic mechanisms within the amygdala to alter memory processing.
Related Concept Videos
Analgesia and Pain Management
Regulation of Food Intake
Role of Amygdala in Memory
One of the...

